Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Argus Health
UBS
Fuji
AstraZeneca
Moodys
Covington
Colorcon
Deloitte

Generated: May 25, 2018

DrugPatentWatch Database Preview

GANCICLOVIR SODIUM Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Ganciclovir Sodium patents expire, and what generic alternatives are available?

Ganciclovir Sodium is a drug marketed by Pharmascience Inc and West-ward Pharms Int and is included in two NDAs.

The generic ingredient in GANCICLOVIR SODIUM is ganciclovir sodium. There are twenty-five drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the ganciclovir sodium profile page.
Drug patent expirations by year for GANCICLOVIR SODIUM
Synonyms for GANCICLOVIR SODIUM
02L083W284
107910-75-8
6H-Purin-6-one, 1,9-dihydro-2-amino-9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-, monosodium salt
6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-, monosodium salt
6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-, sodium salt
82410-32-0 (Parent)
84245-13-6
9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine, monosodium salt
AB0016776
AC1Q1VAA
AKOS015896059
API0024397
BS-1004
C9H12N5NaO4
CHEMBL1200850
Cytovene IV
Cytovene IV (TN)
D04301
FT-0656038
Ganciclovir sodium (unspecified MF)
Ganciclovir sodium (USAN)
Ganciclovir sodium [USAN]
Ganciclovir Sodium Salt
HE004149
I06-1697
J-002034
JJICLMJFIKGAAU-UHFFFAOYSA-M
K-0587
KS-00002WRY
MFCD00873979
MolPort-020-313-387
Natclovir
P006
RS 21592 Sodium
RS-21592 sodium
SC-47228
SCHEMBL149822
Sodium 2-amino-1,9-dihydro-9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6H-purin-6-one
sodium 2-amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-9H-purin-6-olate
sodium 2-amino-9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}-9h-purin-6-olate
ST51053198
UNII-02L083W284

US Patents and Regulatory Information for GANCICLOVIR SODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmascience Inc GANCICLOVIR SODIUM ganciclovir sodium INJECTABLE;INJECTION 207645-001 Dec 8, 2017 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
West-ward Pharms Int GANCICLOVIR SODIUM ganciclovir sodium INJECTABLE;INJECTION 076222-001 Jul 16, 2003 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
QuintilesIMS
Boehringer Ingelheim
Baxter
Teva
Chinese Patent Office
Deloitte
Covington
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.